- Home
- NRIX vs AMBQ Comparison
NRIX vs AMBQ Comparison
Compare NRIX & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- AMBQ
- Stock Information
- Founded
- NRIX 2009
- AMBQ 2010
- Country
- NRIX United States
- AMBQ United States
- Employees
- NRIX N/A
- AMBQ N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- AMBQ Semiconductors
- Sector
- NRIX Health Care
- AMBQ Technology
- Exchange
- NRIX Nasdaq
- AMBQ Nasdaq
- Market Cap
- NRIX 750.4M
- AMBQ 673.1M
- IPO Year
- NRIX 2020
- AMBQ 2025
- Fundamental
- Price
- NRIX $12.00
- AMBQ $29.83
- Analyst Decision
- NRIX Strong Buy
- AMBQ Buy
- Analyst Count
- NRIX 14
- AMBQ 4
- Target Price
- NRIX $26.64
- AMBQ $41.75
- AVG Volume (30 Days)
- NRIX 1.7M
- AMBQ 145.4K
- Earning Date
- NRIX 10-09-2025
- AMBQ 11-06-2025
- Dividend Yield
- NRIX N/A
- AMBQ N/A
- EPS Growth
- NRIX N/A
- AMBQ N/A
- EPS
- NRIX N/A
- AMBQ N/A
- Revenue
- NRIX $83,687,000.00
- AMBQ $74,210,000.00
- Revenue This Year
- NRIX $58.48
- AMBQ N/A
- Revenue Next Year
- NRIX N/A
- AMBQ $25.34
- P/E Ratio
- NRIX N/A
- AMBQ N/A
- Revenue Growth
- NRIX 48.32
- AMBQ N/A
- 52 Week Low
- NRIX $8.18
- AMBQ $28.61
- 52 Week High
- NRIX $29.56
- AMBQ $51.76
- Technical
- Relative Strength Index (RSI)
- NRIX 66.65
- AMBQ N/A
- Support Level
- NRIX $10.28
- AMBQ N/A
- Resistance Level
- NRIX $11.70
- AMBQ N/A
- Average True Range (ATR)
- NRIX 0.79
- AMBQ 0.00
- MACD
- NRIX 0.24
- AMBQ 0.00
- Stochastic Oscillator
- NRIX 98.06
- AMBQ 0.00
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.